Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
Relvar® Ellipta® 100/25 mcg gains approval in Japan for use in patients with COPD
Relvar is a combination of the inhaled corticosteroid, fluticasone furoate, and the long-acting beta2 agonist, vilanterol ‘VI’.
GSK announces EU regulatory submission of candidate vaccine for prevention of shingles - Follows regulatory submissions in US and Canada
Tthe regulatory submission of a MMA to the EMA seeking approval for ShingrixTM.
GSK starts phase III programme with daprodustat for anaemia associated with chronic kidney disease
The start of a phase III development programme investigating daprodustat as a treatment for anaemia associated with CKD.
GSK announces phase lll study of mepolizumab meets co-primary endpoints and all secondary endpoints in patients with eosinophilic granulomatosis with polyangiitis
Both co-primary endpoints and all secondary endpoints were met in a pivotal phase III study.
GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
COPD is a disease of the lungs that includes chronic bronchitis, emphysema or both.
ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders
GSK receives FDA approval for expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and older
An approval from the US Food and Drug Administration’s (FDA) Center
GSK’s Benlysta® (belimumab) shows sustained benefits in patients with SLE
GSK today announced results from a 7-year safety and efficacy continuation study for Benlysta® (belimumab).
GSK announces new data from phase III studies of sirukumab in adult patients with moderately to severely active rheumatoid arthritis
Sirukumab is being co-developed as part of a collaboration with Janssen Biologics (Ireland) [Janssen].
GSK leads Access to Medicine Index 2016
GSK has today been ranked first in the Access to Medicine Index for the fifth consecutive time.
GSK announces positive results in fourth consecutive pivotal trial of Benlysta® (belimumab) in SLE
Data in Japan, China and South Korea will form basis of new regulatory submissions for Benlysta
GSK statement in response to New York Times article on China
These matters relating to our operations in China were deeply disappointing to GSK.
GSK presents new data for shingles candidate vaccine at IDWeek scientific conference
GSK today announced new data for its shingles candidate vaccine ShingrixTM.
Results Announcement for the third quarter 2016
GSK delivers sales growth, improved cash flow and sustained pipeline progression in Q3.
GSK announces US regulatory submission of candidate vaccine for prevention of shingles
Regulatory submissions in the EU and Canada remain on track for 2016
New data published for GSK’s Nucala investigating hospitalisation reduction in severe asthma patients with an eosinophilic phenotype
The risk of hospitalisations or emergency room visits caused by asthma attacks was halved (51% reduction p<0.001) in severe asthma patients
GlaxoSmithKline completes sale of remaining Aspen shares
GSK has agreed to the sale of 28.2 million ordinary shares in Aspen Pharmacare Holdings Ltd ("Aspen") at a price of ZAR 300 per share.
GlaxoSmithKline plc appoints Brian McNamara as CEO of GSK Consumer Healthcare
Brian join GSK’s Corporate Executive Team and will continue as a member of the Board of the Consumer Healthcare Joint Venture with Novartis.
GlaxoSmithKline announces intention to sell remaining holding in Aspen
GSK intends to sell its remaining stake in Aspen Pharmacare Holdings Ltd ("Aspen").
GSK announces regulatory submissions for subcutaneous formulation of Benlysta® (belimumab) for patients with systemic lupus disease
It has filed regulatory submissions in the US and Europe for Benlysta® (belimumab) for approval.